A growing recognition of the health impact of social risks – such as food insecurity and homelessness – has prompted researchers, healthcare providers and policymakers to consider ways to address these risk factors as part of holistic clinical care.
Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH – Psychedelic Alpha
VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical
September 6, 2023